New Zealand markets closed

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.8000-0.1000 (-3.45%)
At close: 04:00PM EST
2.9400 +0.14 (+5.00%)
After hours: 05:04PM EST

Ocular Therapeutix, Inc.

24 Crosby Drive
Bedford, MA 01730
United States
781 357 4000

Full-time employees228

Key executives

NameTitlePayExercisedYear born
Mr. Antony MattessichPres, CEO & Director1.04MN/A1967
Mr. Donald Notman Jr.Chief Financial Officer629.17kN/AN/A
Dr. Peter K. Jarrett Ph.D.Chief Scientific OfficerN/AN/A1957
Mr. Philip C. StrassburgerGen. CounselN/AN/A1960
Mr. William H. Ransone IIVP of Global Sales & MarketingN/AN/AN/A
Ms. Tracy SmithVP of HRN/AN/AN/A
Mr. Scott CorningSr. VP of CommercialN/AN/AN/A
Mr. Christopher G. WhiteChief Bus. OfficerN/AN/A1962
Dr. Rabia Gurses Ozden M.D.Chief Medical OfficerN/AN/A1968
Dr. Karen-Leigh Edwards M.B.A., Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Corporate governance

Ocular Therapeutix, Inc.’s ISS governance QualityScore as of 1 December 2022 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.